Newron Secures FDA Type A Meeting to Address ENIGMA-TRS 2 Clinical Hold in United States

Newron Pharmaceuticals has completed a Type A meeting with the FDA to address the clinical hold placed on U.S. enrollment in its ENIGMA-TRS 2 trial, a step that defines the regulatory pathway any sponsor must clear before a held study can resume. For regulatory affairs leads managing active INDs, the meeting outcome signals what the agency currently requires as a condition for restart, and sets a documentation and protocol-amendment benchmark worth tracking.

Type A meetings are reserved for matters the FDA considers immediately necessary to resolve a clinical hold, making the agency's agreement to convene a substantive indicator of where the review stands. During the meeting, Newron and FDA discussed the specific changes required for the study to potentially restart enrollment in the United States. The precise nature of those changes has not been publicly disclosed, but the meeting itself marks a defined procedural milestone under 21 CFR Part 312 clinical hold regulations.

ENIGMA-TRS 2 is evaluating evenamide in treatment-resistant schizophrenia, a patient population with limited approved options and a regulatory pathway that demands rigorous safety oversight. The U.S. hold does not affect trial sites operating outside the country, meaning the global dataset continues to accumulate while the domestic enrollment question remains open.

For QA directors and regulatory operations teams, the relevant read here is process: a Type A meeting outcome typically requires the sponsor to submit a complete response addressing each FDA objection, after which the agency has 30 days to lift or maintain the hold under standard IND review timelines. How comprehensively Newron addresses the required changes in that submission will determine whether U.S. sites re-open within the current trial window or face a longer interruption to the enrollment timeline.

The next measurable checkpoint is Newron's formal response submission to the FDA incorporating the agreed protocol and procedural changes discussed at the Type A meeting.

Source: Media4Growth via Indian Pharma Post, 7 July 2026.